Background and purpose: Besides a distinct spectrum of demyelinating syndromes, encephalitis was observed in patients with myelin oligodendrocyte glycoprotein antibodies (MOG-abs). Methods: The clinical records of 690 patients with idiopathic demyelinating diseases of the central nervous system seen in our center from June 2015 to December 2017 were retrospectively reviewed. All underwent serum aquaporin 4 antibody (AQP4-ab) and MOG-ab detection by cell-based assays as a routine diagnostic approach. Patients with MOG-abs or AQP4-abs who had ever experienced an encephalitis-like illness during the disease course were identified. Whether diagnoses of possible or definite autoimmune encephalitis could be reached with regard to these particular episodes of encephalitis was determined. The incidence and clinical features of encephalitis in anti-MOG disease are described in detail and compared with those in anti-AQP4 disease. Results: Amongst the 690 patients, 87 were MOG-ab-positive whilst 140 were AQP4-ab-positive. 20.7% (18/87) of the MOG-ab-positive patients had typical presentations of encephalitis. Unique cortical lesions (72.2%, 13/18) were observed; fever (55.6%), intracranial hypertension (41.2%) and cerebrospinal fluid pleocytosis (64.7%) were common during MOG-ab-associated encephalitis. Sixteen of the 18 patients fulfilled the criteria of definite autoimmune encephalitis (specific disease with MOG-ab) during encephalitis, and five patients overlapped with anti-N-methyl-D-aspartate-receptor encephalitis (NMDARE). Only 3.6% (5/140) of the AQP4-ab-positive patients had encephalitis, and none overlapped with NMDARE. The Expanded Disability Status Scale scores and the Cerebral Functional System Scores at last followup were lower in patients with MOG-ab-associated encephalitis than in those with AQP4-ab-associated encephalitis. Conclusions: Encephalitis should be recognized as an important clinical component in anti-MOG diseases.
Introduction
Myelin oligodendrocyte glycoprotein (MOG) is a membrane protein expressed on oligodendrocyte cell surfaces and the outermost surface of myelin sheaths. With the introduction of highly specific cell-based assays, conformation-sensitive anti-MOG antibodies have been detected in a distinct spectrum of central nervous system (CNS) inflammatory demyelinating diseases (IDDs) with clinical phenotypes partly overlapping acute disseminated encephalomyelitis (ADEM) [1] or aquaporin 4 antibody (AQP4-ab) negative neuromyelitis optica spectrum disorders (NMOSD) [2] . However, the pathology of MOG-antibody (MOG-ab) diseases is characterized by prominent demyelination with astrocytes being preserved, fundamentally different from the astrocytopathy typically seen in AQP4-ab-positive NMOSD [3] . Notably, encephalitis and epilepsy are observed in patients with MOG-ab and are seldom seen in patients with AQP4-ab [4] [5] [6] .
In fact, MOG-ab was integrated into the clinical approach to the diagnosis of autoimmune encephalitis (AE) as one of the specific auto-antibodies in a recent position paper [7] . An epidemiological survey conducted in Olmsted County, Minnesota, USA, showed that the prevalence of definite AE with MOG-abs was 1.9/100 000, higher than that of leucine-rich glioma-inactivated protein 1 (LGI1; 0.7/100 000) and N-methyl-D-aspartate receptor (NMDAR; 0.6/100 000) antibody-associated AE [8] . In our clinical practice, more patients with anti-MOG diseases that have experienced encephalitis are being encountered; some overlap with anti-NMDAR encephalitis (NMDARE).
In the current study, the aim was to further characterize the incidence and clinical features of encephalitis in anti-MOG diseases, and to compare the features and outcomes of MOG-ab-associated encephalitis with those of AQP4-ab-associated encephalitis.
Patients and methods

Patients
From June 2015 to December 2017, 690 consecutive patients (all of Han Chinese ethnicity) with suspected CNS IDDs were seen in the Neuromyelitis Optica and Multiple Sclerosis Clinic at Huashan Hospital, Shanghai Medical College, Fudan University (Shanghai, China). All of them underwent serum MOG-ab and AQP4-ab detection using cell-based assays as part of the routine diagnostic approach (Fig. 1) .
Upon reviewing the clinical, magnetic resonance imaging (MRI) and laboratory records of these patients, patients with MOG-ab or AQP4-ab who had ever experienced an encephalitis-like illness during the disease course were identified. Whether diagnoses of possible or definite AE could be reached with regard to these particular episodes of encephalitis was determined. The incidence and clinical features of encephalitis in anti-MOG disease were described in detail and compared with those in anti-AQP4 disease. The Expanded Disability Status Scale (EDSS) score, the Cerebral Functional System Score (CFSS) and the modified Rankin scale (mRS) score at last follow-up were utilized to estimate the disease outcome of the patients with encephalitis.
Written informed consent was obtained from each participant. The study was approved by the Medical Ethics Committee of Huashan Hospital, Shanghai Medical College, Fudan University.
Methods
Details of the methods are shown in Appendix S1.
Results
Demographic data
Amongst the 690 patients with CNS IDDs, 87 were MOG-ab-positive and 140 were AQP4-ab-positive (Fig. 1) . The demographic data of the anti-MOG and anti-AQP4 cohort are listed in Table S1 .
Eighteen of the 87 (20.7%) MOG-immunoglobulin G (IgG)-positive patients had presented with acute or subacute onset of psychiatric symptoms, decreased or altered level of consciousness, lethargy, personality change or working memory deficits during the disease course based on clinical records. Of them, eight were female and 10 were male. The median disease onset age was 22 years (mean 21.3 AE 8.4 years, range 9-38 years). Disease started in childhood (<14 years) in five patients. With the cerebrospinal fluid (CSF) findings, electroencephalograph alterations and MRI features, all of the 18 patients met a diagnosis of encephalitis (Table S2) .
Five of the 140 (3.6%) AQP4-ab-positive patients had experienced an encephalitis episode. All of them were females, with a median onset age of 38 years (range 16-52 years).
Disease course and onset presentation
The median disease duration of the 18 MOG-ab-positive patients with encephalitis was 24 months (mean 28.4 months, range 5-114 months). Until the last follow-up, 72.2% (13/18) had a relapsing-remitting course, whereas 27.8% (5/18) had a monophasic course (Table S2) .
Twelve of the 18 (66.7%) patients presented with encephalitis during their first episode. The remaining six (33.3%, 6/18) patients initially presented with unilateral or bilateral optic neuritis (ON) at onset, and then developed encephalitis during subsequent episodes. Two patients (patient 7 and patient 18) experienced two episodes of encephalitis during the disease course; the remaining 16 patients (88.9%, 16/18) had only one episode of encephalitis up to the last followup (Table S2) .
Clinical manifestations throughout the disease duration
During the particular episodes of encephalitis, all of the 18 MOG-ab-positive patients presented with typical symptoms, such as headache, decreased level of consciousness, lethargy, disorientation, irritability, euphoria, abnormal behavior or speech, hallucinations, psychosis, change of personality, social withdrawal, memory decline or cognitive decline. Ten (55.6%, 10/18) patients had fever, nine (50.0%, 9/18) patients had seizure and one patient (patient 1) had trunk dyskinesias and hypoventilation during encephalitis (Table S2) .
Furthermore, 13 of the 18 (72.2%) MOG-ab-positive patients had ON attacks, two patients (11.1%) had myelitis and six patients (33.3%) had acute brainstem syndromes throughout the disease duration (Table S2) .
Neuro-imaging
The brain MRI images of the 18 MOG-ab-positive patients obtained during the episodes of encephalitis were reviewed. Cortical lesions were the most frequently observed and were best depicted by T2 fluid-attenuated inversion recovery (FLAIR) images. Altogether, 13 of the 18 (72.2%) patients had cortical involvement. Amongst them, six patients (33.3%, 6/ 18) had frontal and/or parietal cortical lesions close to the cerebral falx ( Fig. 2a-h) ; striking serpentine or twisting enhancement along the cortical lesion was observed in three of the six patients ( Fig. 2b-d , f and h). Five patients (27.8%, 5/18) had diffuse cortical lesions located in the unilateral hemisphere ( Fig. 2i-l) , with or without corresponding leptomeningeal enhancement (Fig. 2j ). In the remaining two patients (patient 6 and patient 9), cortical lesions were invisible on MRI but were confirmed by positron emission computed tomography ( Fig. 2m and n) . Moreover, cortical lesions were seen to develop alone (7/13) or were accompanied by lesions with demyelination features in deeper structures (6/13). During encephalitis, brain lesions were also observed in the temporal lobe or limbic system (38.9%, 7/18; Fig. 2o and p) ; in the subcortical white matter of the parietal lobe (33.3%, 6/18), frontal lobe (16.7%, 3/18) or occipital lobe (5.6%, 1/18); in the deep white matter adjacent to the lateral ventricle (5.6%, 1/18); or in the corpus callosum (11.1%, 2/18).
The involvement of deep midline structure, such as brainstem and brachium pontis (44.4%, 8/18), thalamus (27.8%, 5/18) or peri-third ventricle area (16.7%, 3/18), was also observed during encephalitis (Table S3 ).
Laboratory findings
The serum MOG-ab titers ranged from 1:10 to 1:320 in the 18 patients with encephalitis. For patient 3 and patient 5, MOG-abs were tested during a subsequent ON attack following encephalitis; the remaining patients were tested for MOG-abs during the acute phase of encephalitis (Table S4) .
Lumbar punctures were performed at the earliest available time in 17 of the 18 patients during encephalitis. Seven patients (41.2%, 7/17) had an increased intracranial pressure over 200 mmH 2 O, 11 patients (64.7%, 11/17) had CSF pleocytosis and three patients (25%, 3/12) exhibited a positive CSF oligoclonal band. Anti-nuclear antibody was positive in five patients (27.8%, 5/18) and Ro-52 was mildly positive in one patient (Table S4) .
The CSF and serum anti-NMDAR (GluN1 subunit), LGI1, anti-contactin-associated-protein-2 (CASPR2), anti-alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPAR) and antic-aminobutyric acid-B receptor (GABA(B)R) IgGs were tested in 15 of the 18 patients. Of them, five were positive for CSF anti-NMDAR antibody during encephalitis. One patient (patient 5) exhibited a negative result during encephalitis but became anti-NMDAR-positive during a subsequent ON. No patients were positive for the LGI1, CASPR2, AMPAR or GABA(B)R antibodies (Table S4) .
Treatment response
All of the 18 MOG-ab-positive patients received highdose methylprednisolone therapy, with or without intravenous IgG, during the acute phase of encephalitis. Four patients were empirically treated with ganciclovir on the basis of immunotherapy. Before treatment, the mRS and CFSS values were 3.75 AE 0.64 (range 3-5) and 3.70 AE 0.80 (range 2-5), respectively, and by the last follow-up these values had dropped significantly to 0.89 AE 0.83 (range 0-3; P < 0.001) and 1.17 AE 1.10 (range 0-3; P < 0.001). A faint residual white matter lesion was observed in patient 2, and temporal lobe atrophy was observed in patients 16 and 18 in follow-up MRI studies. In the remaining patients, the lesions acquired during encephalitis were completely resolved after treatment.
Diagnostic determination
The diagnoses with respect to these particular episodes of encephalitis were determined according to the diagnostic criteria of AE [7] . Combined with the clinical context as well as MRI and CSF changes, a diagnosis of possible AE was reached in all the 18 MOG-abpositive patients (Table S1) .
To obtain a more specific diagnosis, the MOG-ab status was further included on the basis of a preliminary possible AE diagnosis following the proposed clinical approach [7] . It turned out that 16 patients fulfilled the criteria for definite AE (specific disease with MOG-ab), whereas two patients (patient 3 and patient 5) did not because their MOG-abs were not tested during encephalitis (Fig. 1, Table S1 ).
Six of the 18 MOG-ab-positive patients were positive for CSF anti-NMDAR antibody. Based on the proposed diagnostic criteria, five of the six patients were diagnosed as having overlapping NMDARE [7] . The remaining patient (patient 5) was not diagnosed as NMDARE because his anti-NMDAR antibody was negative at the time of encephalitis (Fig. 1 , Tables  S1 and S4) . Accordingly, the five AQP4-ab-positive patients with encephalitis also conformed to the criteria of definite AE (specific disease with AQP4-ab) [7] . However, none of them overlapped with NMDARE, as anti-NMDAR antibodies were absent in their CSF or serum (Fig. 1, Table S1 ).
The comparison between encephalitis in patients with MOG-ab and AQP4-ab
Episodes of encephalitis were much more common in patients with MOG-abs than in patients with AQP4-abs (20.7% vs. 3.6%; P < 0.001), and the proportion of overlapping NMDARE was higher in the MOGab-positive cohort than in the AQP4-ab-positive cohort (5.7% vs. 0%; P = 0.008; Fig. 1, Table S1 ).
Patients positive for MOG-abs tended to have more frequent cortex involvement during encephalitis (P = 0.052), whereas deep cerebral white matter and corpus callosum lesions were more common in patients with AQP4-abs during encephalitis (P = 0.017). The outcomes of MOG-ab-positive patients with encephalitis seemed to be better, with significantly lower EDSS (P = 0.022) and CFSS (P = 0.005) at last follow-up. 94.4% of the MOG-ab-positive patients with encephalitis and 60% of the AQP4-ab-positive patients with encephalitis achieved a favorable outcome (mRS score 0-2 at last follow-up), although the comparison did not reach statistical significance (P = 0.102; Table 1 ).
Discussion
The whole clinical spectrum of anti-MOG diseases still needs to be clearly defined. Recently, unique cortical encephalitis was reported in five Japanese cases with MOG-abs [4, 5] . In a cohort study in the UK, seizure and encephalitis were observed in five out of 34 patients with MOG-abs [6] . In our cohort, nearly onefifth (20.7%) of the MOG-ab-positive patients had encephalitis, all conformed to the diagnostic criteria of possible AE, and 18.4% fulfilled the diagnostic criteria of definite AE (specific disease with MOG-abs). These findings strongly suggest that encephalitis is an important clinical component of MOG-ab-associated demyelination, making the clinical spectrum of anti-MOG diseases wider than imagined.
In more complicated situations, MOG-IgG disease can coexist with NMDARE [9, 10] . Herein, five of the 18 patients with MOG-ab-associated encephalitis had overlapping NMDARE. In these particular cases it is extremely difficult, even impossible, to tell whether the encephalitis or seizure is attributed to MOG or NMDAR antibodies. However, this problem does not affect the direction of treatment. Considering that oligodendrocytes do contain NMDAR [11] , it is reasonable to speculate that the immune attack targeting myelin may simultaneously involve NMDAR, and vice versa.
The MRI herein during MOG-ab-associated encephalitis is impressive and unique, with cortical lesions observed the most frequently. Frontal and/or parietal cortical lesions that were close to the cerebral falx, with serpentine enhancement along the cortical lesion, were striking and quite similar to a previous report [4] . Another type of cortical lesion was located in the unilateral hemisphere and can be accompanied by corresponding leptomeningeal enhancement. Unilateral cortical lesions, when developed in the temporal or occipital lobes, can mimic those seen in CreutzfeldtJakob disease or mitochondrial encephalomyopathy. Except for cortical involvement, lesions in the temporal lobe or limbic system have also been observed and are similar to those seen in limbic or herpes simplex encephalitis.
Notably, the clinical diagnosis of AE can overlap with ADEM, as they share clinical features of encephalopathy. In the MOG-ab-positive encephalitis cohort, patients 2, 14 and 17 met the criteria of ADEM by having large white matter lesions. However, patient 2 had cortical involvement, which is atypical for ADEM (Fig. 2e, asterisk) . Patient 17 had only one larger, swelling white matter lesion, but a single unilateral lesion is also atypical of ADEM, which usually exhibits multifocal lesions. If the diagnostic algorithm [7] is strictly followed these three patients would be considered to have AE rather than ADEM because of having specific auto-antibodies.
The role of infectious agents in triggering MOG-ab production is still a matter of debate. During MOG-abassociated encephalitis, fever (55.6%), elevated intracranial pressure (41.2%) and CSF pleocytosis (64.7%) are common. However, none of the patients had a confirmed infectious pathogen. Given the distinctive lesions found on MRI, which mimicked those in previously reported MOG-ab-positive encephalitis cases; the typical demyelination episode, such as ON or myelitis following or preceding the encephalitis; and the definite presence of MOG-IgG in the serum, as well as the immunotherapy responsiveness, the encephalitis is considered to be mainly of autoimmune origin.
As was also seen in previous studies [10] , the frequency of encephalitis (3.6%) and coexistence of anti-NMDAR antibody (0%) was much lower in the AQP4-ab-positive cohort than in the MOG-ab-positive cohort. Deep cerebral white matter and corpus callosum lesions were the most commonly seen during encephalitis associated with AQP4-ab, different from the anti-MOG encephalitis in which the cortex was the most frequently involved. The EDSS and CFSS of anti-MOG encephalitis at last follow-up were lower, indicating a better prognosis compared to AQP4-ab-associated encephalitis.
In summary, our study showed that encephalitis should be recognized as an important clinical phenotype of anti-MOG diseases. Further verification of the results in prospective, larger-scale, multicenter studies is warranted.
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